NEW YORK (GenomeWeb News) – Caprotec Bioanalytics said today that it has raised €4.5 million ($6.6 million) through investments from VC Fonds Berlin, the ERP Startfonds, and from other private investors.
The company plans to use the money to develop and sell its CCMS proteomics analysis technology, which uses tri-functional molecules called capture compounds and complements 2D gel electrophoresis and affinity chromatography. The capture compounds serve as chemical probes by detecting proteins directly in solutions, the company said.
The startup plans to initiate operations by moving into new facilities in Berlin-Adlershof and staffing up. Caprotec also will begin developing kits for proteomics R&D and for drug and biomarker development.